Inflarx N.V. cash flow statement

In fiscal 2025, Inflarx N.V.'s operations generated −$39.9m of cash.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Inflarx N.V.: cash flow statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash from operations	−41	−53	−40
Stock-based pay	4	4	5

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Lyell Immunopharma, Inc. cash flow
AIM Immunotech Inc. cash flow
Ibio, Inc. cash flow
Lisata Therapeutics, Inc. cash flow
Celldex Therapeutics, Inc. cash flow

Head to head: IFRX vs LYEL AIM vs IFRX IBIO vs IFRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inflarx N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inflarx N.V.